News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Accelr8 Technology Corporation (OTC-BB: ACLY) Announces Second Supply Agreement And Expanded Original Agreement With SCHOTT Nexterion


10/19/2005 5:08:52 PM

DENVER, June 9 /PRNewswire-FirstCall/ -- Accelr8 Technology Corporation and SCHOTT Nexterion (SCHOTT JENAer GLAS GmbH, Jena, Germany) announced today the signing of a new supply agreement for Nexterion(R) Slide HS microarray slides using Accelr8's OptiChem(R) surface chemistry. The two companies also expanded a previous supply agreement for Accelr8 to produce Nexterion(R) Slide H for SCHOTT.

Accelr8 has been manufacturing Slide HS for SCHOTT since October, 2004. Under the new agreement Accelr8 will extend production through December, 2005. SCHOTT also has a right during 2005 to enter into negotiations for an exclusive manufacturing and distribution license, similar to the Slide H agreement signed November 4, 2004.

Under a prior supply agreement for Slide H, Accelr8 fulfilled the terms as planned, but Nexterion sales exceeded forecast. Therefore Nexterion requested an extension for more products while Nexterion's own production line ramps up.

According to David Howson, Accelr8's president, "under the two agreements we estimate that product revenues from Nexterion to Accelr8 will total approximately $150,000 for the remainder of this calendar year."

The ongoing revenues from Slide H and Slide HS production and licensing occur in parallel with Accelr8's primary business focus in developing the BACcelr8r(TM) rapid bacterial analysis system. The company intends the BACcelr8r to become the world's first diagnostic system to provide complete bacterial antibiotic resistance strain identification in 8 hours or less. Conventional culturing typically delays lab results from one to three days, which is inadequate for best management of rapidly progressing, life- threatening infections in critically ill patients.

Microarraying techniques allow researchers to study massive numbers of genes and proteins in parallel. The technology is based on placing thousands of different types of biomolecules onto a surface such as a glass microarray slide. Microarraying has already had a major impact in fields ranging from cancer research to agriculture, and is rapidly moving from a discovery research tool to broader applications in medical diagnostics. Accelr8's OptiChem coating licensed by SCHOTT Nexterion provides unique performance advantages that help to make SCHOTT's slides an enabling component of next generation microarrays.

"We're very pleased at the market's response to Slide H and now initial acceptance of Slide HS by a significant industrial customer," said Dr. Lutz Wehmeier, SCHOTT Nexterion's General Manager. "As part of Nexterion's comprehensive microarraying product line for DNA as well as protein applications, we value Accelr8's innovative coating technology in advancing the performance and adaptability of microarray analysis."

The HS slide provides a streptavidin surface, which is a type of protein pre-attached to the slide, instead of a chemical reaction linker. The new coating provides a very uniform surface to maximize detection sensitivity. Streptavidin is a natural bacterial protein that forms an extremely strong and specific bond with biotin, a small vitamin molecule, which is widely used as a molecular linker for proteins, DNA, and other molecules. Streptavidin and biotin make a popular molecular construction set for building analytical assays.

"Accelr8's Slide HS technology is important because of the wide familiarity and easily-available commercial kits for binding biotin to the scientist's target materials, something that all virtually all biomedical scientists know how to do and feel comfortable with," said Howson. "It's the easy route -- like a biochemical Lego(R) set -- to assay design."

About Accelr8

Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. In addition to its microarraying products, Accelr8 is also developing a rapid clinical pathogen platform, the BACcelr8r(TM), based on its innovative surface coatings, assay processing, and detection technologies.

About SCHOTT

SCHOTT (www.schott.com) is an international technology-driven group that sees its core purpose as the lasting improvement of living and working conditions through special materials, components and high-tech solutions. Its main areas of focus are the household appliances industry, optics and electronics, pharmaceuticals and renewable energies. Schott has a presence in close proximity to its customers through highly efficient production and sales companies in all its major markets. It has 18,500 employees producing worldwide sales of 2 billion euros. The company's technological and economic expertise is closely linked with its social and ecological responsibility.

The division SCHOTT Nexterion Microarray Solutions (www.schott.com/nexterion) is specialized in high quality microarray products. As such, the company develops and markets a wide range of coated and uncoated glass substrates for DNA and protein microarraying under the brand Nexterion(R). SCHOTT Nexterion continuously expands its product portfolio and has several innovative products and services in the development pipeline.

Accelr8 Technology Corporation

CONTACT: Jim Kendrick of Metzger Associates, +1-303-786-7000,jim@metzger.com, for Accelr8; or David Howson of Accelr8 Technology,+1-303-863-8088, david.howson@accelr8.com; or Isabel Eymael of SCHOTTJENAer, GLAS GmbH, +49(0)3641-681-6555, isabel.eymael@schott.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES